Journal article

Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study

Stephanie Archer, Chantal Babb de Villiers, Fiona Scheibl, Tim Carver, Simon Hartley, Andrew Lee, Alex P Cunningham, Douglas F Easton, Jennifer G McIntosh, Jon Emery, Marc Tischkowitz, Antonis C Antoniou, Fiona M Walter



BACKGROUND: There is a growing focus on the development of multi-factorial cancer risk prediction algorithms alongside tools that operationalise them for clinical use. BOADICEA is a breast and ovarian cancer risk prediction model incorporating genetic and other risk factors. A new user-friendly Web-based tool ( has been developed to apply BOADICEA. This study aimed to explore the acceptability of the prototype CanRisk tool among two healthcare professional groups to inform further development, evaluation and implementation. METHOD: A multi-methods approach was used. Clinicians from primary care and specialist genetics clinics in England, France and Germany were invited to use the..

View full abstract

University of Melbourne Researchers


Awarded by Cancer Research UK

Awarded by European Union's Horizon 2020 research and innovation programme

Awarded by Wellcome Trust Collaborative Award

Awarded by Canadian Institutes of Health Research

Funding Acknowledgements

This work was supported by Cancer Research UK grants C12292/A20861; the European Union's Horizon 2020 research and innovation programme under grant agreement numbers 633784 (B-CAST) and 634935 (BRIDGES); a Wellcome Trust Collaborative Award (203477/B/16/Z); and the PERSPECTIVE programme: The Government of Canada through Genome Canada and the Canadian Institutes of Health Research (grant GPH-129344). Jon Emery is funded by an Australian National Health Medical Research Council practitioner fellowship. Marc Tischkowitz acknowledges funding from the European Research Council and Cambridge NIHR Biomedical Research Centre. Fiona Walter is Director of the multi-institutional CanTest Collaborative which is funded by Cancer Research UK (C8640/A23385).